CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week Left Ventricular Assist Devices: Synergistic Model Between Technology and Medicine Vaccination Trends in Patients With Heart Failure - Insights From Get With The Guidelines–Heart Failure Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5) Ejection Fraction Pros and Cons: JACC State-of-the-Art Review Heart Failure With Preserved Ejection Fraction in the Young Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure
|<< 1 2 3 4 5 6 7 ...>>|

Clinical Trial2020 Aug 18;9(16):e015103.

JOURNAL：J Am Heart Assoc. Article Link

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus

K Ejiri, T Miyoshi, MUSCAT‐HF Study Investigators. Keywords: B‐type natriuretic peptide; DM; HF; sodium‐glucose cotransporter 2 inhibitor

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top